Thermostable Vaccine Patents: Who Leads, Where the Gaps Are 2026
- One applicant dominates the ranking. the leading assignee holds 44 of the records tracked in this ranking, against a fifth-place count of 2 and a tenth-place count of 1 — a long tail of single or double-digit filers behind a single lead position.
- Filing activity nearly tripled between 2021 and 2024. from 2 filings in 2021 to 6 in 2024, a +200% rise over that three-year span, before the most recent two years understate activity due to publication lag.
- Claims are concentrated almost entirely in one IPC subclass. A61K covers 96.2% of the 53 records in scope, meaning most filing pressure sits on formulation and preparation claims rather than diagnostics or delivery apparatus.
Filing growth compares 2021 (2 records) with 2024 (6) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
This review covers 53 published patent records filed between 2015 and 2026 that describe thermostable or cold-chain-free vaccine formulations, drawing on claims and descriptions referencing lyophilization cycles, sugar glass stabilizers, residual moisture control, potency retention, reconstitution, and controlled temperature chains. The scope is narrow by design: it captures formulation and process patents rather than the broader universe of vaccine composition filings, so the picture here is one of a specialised sub-field rather than vaccine development as a whole.
Filing activity in this set peaked in 2017 at 8 records and has since moved unevenly, with a documented rise from 2021 to 2024 before the two most recent years, which are still being filled in as publications catch up with filing dates.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 53-record set: how filing activity has moved year over year, and which IPC subclasses carry the claim density.
A three-year rise, understated at the edges
Filings rose from 2 in 2021 to 6 in 2024, a +200% increase over that span. 2017 remains the single highest year on record at 8 filings. The 2025 and 2026 figures are not comparable to earlier years yet, because publication typically lags filing by around 18 months.
Formulation claims dominate the classification spread
A61K (medicinal preparations) appears on 96.2% of the 53 records in scope, making it the near-universal classification for this dataset. A61P (therapeutic activity) follows at 22.6%. The remaining subclasses — C12Q, G01N, C07H and C12M — each sit under 4%, indicating that measurement, sugar-chemistry and bioreactor angles are rarely the primary claim focus even where they appear.
Shares are the percentage of the 53 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Thermostable Vaccine Formulations with Eureka
This page is one run against one query. Ask Eureka your own question about thermostable vaccine formulations and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this set
Thermostable vaccine compositions and methods of preparing same
The disclosure provides compositions relating to thermostable vaccine and methods of preparing same, including methods of preparing thermostable vaccines comprising at least one protein antigen, at least one co-adjuvant such as an aluminium-salt adjuvant, and at least one buffering system containing at least one volatile salt such as ammonium salts, to develop a composition capable of eliciting an immune response in a subject.Filed by Soligenix, published 2023-10-26 as AU2023237223A1.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2012158978A1 | Thermostable vaccine compositions and methods of preparing same | 42 |
| 2 | US20130309273A1 | Thermostable Vaccine Compositions and Methods of Preparing Same | 34 |
| 3 | US20180092851A1 | Thermostable Vaccine Compositions and Methods of Preparing Same | 9 |
| 4 | US20190046632A1 | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibil… | 5 |
| 5 | WO2017147318A1 | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibil… | 4 |
| 6 | US20200384100A1 | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibil… | 3 |
| 7 | US11491111B2 | Thermostable vaccine compositions and methods of preparing same | 3 |
| 8 | EP2709657B1 | Thermostable vaccine compositions and methods of preparing same | 3 |
| 9 | US10751408B2 | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibil… | 2 |
| 10 | US20220265810A1 | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibil… | 1 |
Citation counts reflect influence within the searched corpus and favour older filings; they are not a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the ranking, the trend and the IPC spread are read together.
A single applicant sets the boundary
The leading assignee's 44 records against a fifth-place count of just 2 means most of the claim space that exists has already been staked by one entity. New entrants are more likely to find open ground in adjacent formulation chemistry than in direct reformulation of the lead applicant's core compositions.
Renewed filing activity after a quiet spell
Filings rose from 2 in 2021 to 6 in 2024. That is a real signal of renewed interest in the space, not an artefact of the dataset window, since 2024 is the most recent year that can be treated as complete.
Claims sit almost entirely in one subclass
With A61K present on 51 of 53 records, the field has not meaningfully diversified into adjacent classifications such as measurement (G01N) or sugar chemistry (C07H), each under 4%. That narrow spread suggests the differentiating claims are more likely to be formulation-specific limitations than classification breadth.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to thermostable vaccine formulations, with the prior art for and against each one.
Who is filing, and where the collaboration sits
The ranking returns 10 companies. One pairing accounts for the overwhelming majority of joint-assignee activity in this set.
The dominant filer
One applicant holds 44 of the records captured in this ranking, well ahead of every other entity tracked. Its filings anchor the most-cited records in the set, including the top two by citation count.
A university-industry pairing drives joint filing
The strongest co-assignee pair in this dataset appears 27 times, far ahead of the next pairings at 2 each. That gap indicates a single sustained research partnership rather than a broad pattern of co-filing across the field.
Most other filers hold a handful of records
Below the leader, the ranking falls off quickly to single and low-double-digit counts, down to 1 record at tenth place. This is a field where a small set of individual inventors and one specialty pharma company account for the rest of the tracked activity.
| Assignee | Recent year | YoY |
|---|---|---|
| Stabilitech Pharma LLC | 1 | 0% |
| The Board of Governors of the Colorado State University System | 0 | — |
| Soligenix, Inc. | 0 | — |
| NANDI PRADYOT | 0 | — |
| HASSETT KIMBERLY | 0 | — |
| CARPENTER JOHN | 0 | — |
| BREY ROBERT | 0 | — |
| RANDOLPH THEODORE W | 0 | — |
Where to take this next
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, partnership scouting or white-space filing.
Check freedom-to-operate against the lead applicant
With 44 of the ranked records held by one assignee, any new formulation claim in this space should be checked against that portfolio first, particularly the two most-cited filings.
Run a claims comparison in EurekaTrack the 2021-2024 filing rise as it matures
The +200% increase from 2021 to 2024 is the clearest recent signal in this dataset. Watching which assignees file next, once 2025-2026 data fills in, will show whether this is a broadening trend or one company's cycle.
Set up a monitoring alert in EurekaScope claims around the under-claimed sub-areas
Residual moisture analytics, sugar-glass excipient chemistry and reconstitution device integration each show up in the classification spread without carrying independent claim density, which is where a first-mover claim is more likely to hold.
Explore white space in EurekaCommon questions on thermostable vaccine patents
The assignee ranking for this dataset is led by a single applicant with 44 of the records tracked, well ahead of the next positions, which fall to single or low-double-digit counts by fifth place. The ranking covers 10 companies and individual inventors in total, so it is a narrow field rather than a broad competitive set. Anyone assessing freedom-to-operate here should start with the leader's portfolio, since it also anchors the most-cited filings in the set.
Yes, over the period that can be reliably measured: filings rose from 2 in 2021 to 6 in 2024, a +200% increase. The peak year in the full dataset remains 2017 at 8 filings, so the recent rise has not yet exceeded that earlier high. Figures for 2025 and 2026 are still incomplete because patent publication typically lags the filing date by about 18 months, so those years should not be read as a slowdown.
Almost all records in this dataset, 96.2% of 53, carry the A61K classification for medicinal preparations, which covers formulation and preparation methods such as lyophilization cycles and stabilizer systems. A smaller share, 22.6%, also carries A61P for therapeutic activity claims. Classifications tied to measurement, sugar chemistry and bioreactor apparatus each appear on under 4% of records, meaning the bulk of patent activity is concentrated in formulation composition rather than adjacent measurement or delivery technology.
AU2023237223A1, assigned to Soligenix and published in October 2023, claims compositions and methods for preparing thermostable vaccines that combine at least one protein antigen, a co-adjuvant such as an aluminium-salt adjuvant, and a buffering system built on at least one volatile salt such as an ammonium salt. The claim is built around that specific combination of antigen, adjuvant class and buffering chemistry rather than thermostable vaccines generally. Formulations that avoid volatile-salt buffering systems, or that substitute a non-aluminium adjuvant, sit outside its literal scope, though a full clearance review should check the granted claim set directly.
The classification spread shows measurement and testing methods (G01N), sugar and nucleic acid chemistry (C07H) and bioreactor-related apparatus (C12M) each present on fewer than 4% of the 53 records in scope, despite appearing throughout the formulation-focused filings. That gap suggests residual moisture analytics, sugar-glass excipient chemistry, and reconstitution device integration are documented as supporting technology but rarely claimed independently. A first claim in one of these branches, tied to a specific measurement method or excipient chemistry rather than a broad formulation, is more likely to clear the existing claim density.
Research Thermostable Vaccine Formulations in depth with Eureka
Go past this page: query the whole thermostable vaccine formulations corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.